GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer

There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with defactinib has demonstrated efficacy and a consistent safety profile in two clinical trials in...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of gynecological cancer Vol. 35; no. 11; p. 101832
Main Authors:	Grisham, Rachel, Monk, Bradley J, Van Nieuwenhuysen, Els, Moore, Kathleen Nadine, Fabbro, Michel, O'Malley, David M, Oaknin, Ana, Thaker, Premal, Oza, Amit M, Colombo, Nicoletta, Gershenson, David, Aghajanian, Carol A, Choi, Chel Hun, Lee, Yeh Chen, Mirza, Mansoor Raza, Coleman, Robert L, Cobb, Lauren, Harter, Philipp, Lustgarten, Stephanie, Youssoufian, Hagop, Banerjee, Susana
Format:	Journal Article
Language:	English
Published:	United States Elsevier Limited 01.11.2025
Subjects:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Chemotherapy Clinical trials Clinical Trials, Phase III as Topic Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - pathology Disease control FDA approval Female Humans Kinases Laboratories Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Patients Phosphorylation Randomized Controlled Trials as Topic Response rates Standard of care Toxicity United Kingdom > UK clinical trial FAK Low grade serous ovarian cancer MEK defactinib RAS RAF avutometinib LGSOC
ISSN:	1048-891X, 1525-1438, 1525-1438
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!